Efficacy of topical Bevacizumab in patients diagnosed with dry eye disease compared with conventional treatment

Phase 1

Recruiting

• Conditions: Dry eye disease; Dryness of eye; Keratoconjunctivitis Sicca; eye dryness; xeroma; Bevacizumab

• Registration Number: TCTR20171024002
• Lead Sponsor: The Asia Research Center (ARC) by Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-10-24
• Study Completion: 2017-10-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

1.Patients from outpatient department of the Department of Ophthalmology, King Chulalongkorn Memorial Hospital
2.Patients diagnosed with dry eye disease aged 18 to 80 years old
3.Slit lamp examination Tear Break-Up Time (SLETBUT) <= 5 seconds
4.Patients who can regularly pay a visit as appointed

Exclusion Criteria

1.Any structural abnormalities (such as eyelid trichiasis, entropion, and scarring)
2.The presence of pinguecula or pterygium
3.Active allergy or infection or inflammatory disease at the ocular surface unrelated to dry eye
4.Any inflammation or active structural change in the iris or anterior chamber
5.Glaucoma
6.Diabetes or other systemic, dermatologic, or neurologic diseases that affect the health of ocular surface
7.Use of any other topical medication other than artificial tears within the past month
8.Use of any systemic anti-inflammatory drugs or medication that may interfere with tear production, such as anti-anxiety, anti-depressive, and anti-histamine medications within 3 months
9.Previous punctal occlusion or eye surgery
10.A positive history of refractive surgery or contact lens wear
11.Hypertension that is unstable
12.History of any Bevacizumab contraindications, such as heart failure, gastrointestinal perforation, and pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IKBUT 1-week, 1-month, 3-month Slit-lamp examination test

Secondary Outcome Measures

Name	Time	Method
OSDI 1-week, 1-month, 3-month Questionnaire,Shirmer's 1 test 1-week, 1-month, 3-month Fluorescein clearance timing,Grading ocular surface staining score 1-week, 1-month, 3-month Fluoresceine staining